Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)
APEX-AMI - Pexelizumab in Conjunction With Angioplasty
Sponsor: Procter and Gamble
Listed as NCT00091637, this PHASE3 trial focuses on Acute Myocardial Infarction and remains completed. Sponsored by Procter and Gamble, it has been updated 8 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Procter and Gamble
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Adelaide, Australia , Akron, United States , Albany, United States , Albuquerque, United States , Alessandria, Italy , Alexandria, United States , Alicante, Spain , Alkmaar, Netherlands and 281 more locations